DOCSLIB.ORG

00001432-900000000-9

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
00001432-900000000-9 CE: Alpana; QCO/280107; Total nos of Pages: 9; QCO 280107 REVIEW CURRENT OPINION Advancing the HIV cure agenda: the next 5 years John Thornhill a,b,c, Sarah Fidlera,b,c,Ã, and John Fraterb,d,e,f,Ã Purpose of review To explore how ethical considerations, improved diagnostics and data from clinical trials might see the lowering of some of the barriers blocking a cure for HIV infection over the next 5 years. Recent findings Despite the recent well publicized but eventually disappointing case reports, there remains only one successful HIV cure, the ‘Berlin patient’. We will review the data suggesting that more potent agents might achieve in-vivo viral activation and explore the tantalizing phenomenon of ‘posttreatment control’ following treatment in primary HIV infection. We will also explore how new assays and novel interventions might move the field forward. Summary There is a need for new agents that can be safely tested to impact the viral reservoir, a more meaningful understanding of how to assay patient samples, and research into mechanisms behind how the reservoir is established and impacted by therapy. With HIVþve individuals responding so well to antiretroviral therapy, new trials must be tested hand-in-hand with guidance from patient representatives, especially with respect to determining the acceptable risk. The road to a cure is going to be difficult, but it is vital that inevitable disappointments do not detract from the final goal, which remains worth striving for. Keywords cure, eradication, HIV, latency, reservoir INTRODUCTION the reservoir incorporates numerous assays and The last 5 years has seen increased interest, invest- read-outs – a consensus will be needed. Once ment and engagement in a cure for HIV infection measured, we need to decide whether the drugs becoming a reality [1]. However, despite significant we have to hand, like the histone deacetylase inhibi- scientific and clinical advances, a number of key tors (HDACis), show genuine promise or are just questions remain unanswered and new hurdles have useful as proof of concept for the currently undis- arisen. This review will consider the long-term issues covered agents that may follow. Will monotherapy that may be important for the field to move forward. be adequate or will a second intervention be The prognosis for people living with HIV on required, for example, in the form of immunother- suppressive antiretroviral therapy (ART) is now apy, as in the ‘Kick and Kill’ [4] approach? And, excellent [2]. Accordingly, for those in the field of lastly, what other approaches might enter the arena HIV cure to test unproven and potentially toxic over the next 5 years, and how might technologies interventions [3] or stop successful therapy (especi- ally in the context of the effectiveness of ART to aDivision of Medicine, Wright Fleming Institute, Imperial College, London, prevent onward viral transmission), there needs to bCollaborative HIV Eradication of Reservoirs: UK BRC (CHERUB), be caution. We will evaluate the ethical concerns cImperial National Institute of Health Research Biomedical Research d that need to be considered when researching inter- Centre, London, Nuffield Department of Clinical Medicine, Peter Med- awar Building for Pathogen Research, eInstitute for Emerging Infections, ventions aimed at HIV cure in otherwise healthy The Oxford Martin School and fOxford National Institute of Health people living with HIV on ART. Research Biomedical Research Centre, Oxford, UK A better understanding of the biology and Correspondence to John Frater, Nuffield Department of Clinical Medi- pathogenesis of HIV will assist the design of inter- cine, Peter Medawar Building for Pathogen Research, Oxford, OX1 3SY, ventions aimed at HIV cure. For example, the obser- UK. E-mail: [email protected] vation of posttreatment control (PTC) in which ÃSarah Fidler and John Frater contributed equally to the writing of this some patients stopping ART show no sign of virae- article. mic relapse needs to be further clarified, including Curr Opin Infect Dis 2015, 28:000–000 the mechanisms and predictive markers. Measuring DOI:10.1097/QCO.0000000000000123 0951-7375 ß 2015 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-infectiousdiseases.com Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. CE: Alpana; QCO/280107; Total nos of Pages: 9; QCO 280107 HIV infections and AIDS HIV Association and the Collaborative HIV Eradica- KEY POINTS tion of Reservoirs: UK BRC (CHERUB) collaboration As new interventions aimed at curing HIV move into [12] are excellent examples of this, with over 800 clinical trials, it is vital that research is planned and respondents and the results to be presented in late conducted in conjunction with the patient groups. 2014. Posttreatment control remains an exciting area of cure research, although much more data are needed. Is cure research a peccadillo of wealthier An algorithm of biomarkers to help identify individuals nations or can it have global impact? who could stop therapy to test for cure or virological A scalable, affordable solution for all people living remission is an important target. with HIV must be the goal of any cure strategy, A cure for HIV is likely to comprise a cocktail of particularly in resource-limited regions where the interventions and may involve significant toxicity. burden of HIV disease is greatest. In view of region- specific priorities, any diversion of funding from HIV prevention, vaccine development or ART roll- out must also be balanced appropriately. As – at least and knowledge from other fields be applied to cur- initially – most cure-related research is unlikely to ing HIV? Underpinning all of these issues is a need impact the vast majority of individuals living with for the field to agree on the definitions of the con- HIV, for example, in the sub-Saharan Africa, it is cepts of ‘latency’, the ‘reservoir’ and even ‘cure’. For vital that key priorities are not overlooked. How- example, latency might be considered as a state of ever, this should not replace the need for proof-of- transcriptional silence with no (or rare) viral trans- concept research, much of which will be conducted cripts and no virion production. The extent to where resources are available, and which might then which a latent cell can be activated to produce a be scaled up into more comprehensive studies. replication-competent virus varies, and ongoing basic research is still needed to understand these processes and the reversibility of latency. Is it safe or ethical to stop antiretroviral therapy? The only true test of HIV cure is to stop therapy and ETHICAL CONSIDERATIONS assay for the return of viraemia. However, the safety In light of the excellent prognosis for HIVþve indi- of this remains contentious. Not only might the viduals on ART, potential ethical implications need return of viral replication be pathogenic and risk to be considered when proposing any new trials onward transmission, but also it remains unclear as or interventions. to the extent to which rebound viraemia after treat- ment interruption might replenish the reservoir to such an extent that the participant may not be Investigating a healthy population eligible for further interventions for a prolonged Research into curing HIV infection engenders a period. One of the difficulties is the lack of predic- number of important ethical considerations [5,6]. tive assays that could identify individuals prior to Life expectancy for people living with HIV and viral rebound [13], which could also potentially receiving ART approaches that of the general popu- increase the risk of onward viral transmission. The lation [2,7]. This is despite potential lifelong ART- only safe option therefore for individuals enrolling related toxicities and the increased inflammation into cure approach trials with treatment interrup- and immune activation observed for individuals on tion is to include very frequent viral load testing. suppressive therapy [8–10]. With this in mind, any How frequently viral load needs to be checked and clinical trials of potentially toxic interventions for how long after treatment interruption is assessing HIV cure must have strict safety and unknown, although it is clear that when viraemia acceptability safeguards in place. Furthermore, full returns it can do so abruptly and to high levels [13]. and transparent engagement with community and With these uncertainties in mind, significant coun- industry partners as well as policy makers in the selling of these risks and monitoring for rebound design of such trials will be paramount [11]. For will be needed in any stopping protocol. example, garnering opinion from those living with The data are mixed. In the SMART study, treat- HIV will help set the boundaries for what interven- ment interruption caused a significant increase in tions and trials might be considered acceptable – the risk of all-cause mortality amongst those in the questionnaires such as that run across the UK in discontinuation arm compared with controls who conjunction with Public Health England, the British remained on suppressive therapy [14]. The mean 2 www.co-infectiousdiseases.com Volume 28 Number 00 Month 2015 Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. CE: Alpana; QCO/280107; Total nos of Pages: 9; QCO 280107 Advancing the HIV cure agenda Thornhill et al. length of treatment interruption in SMART was insights they may provide for a scalable approach to 16.8 months, as restarting ART was guided primarily cure, particularly in the setting of changing WHO by CD4 T-cell count, rather than viral load as it ART initiation guidelines [20,21]. would be for a cure-based intervention. Although After treatment interruption, it is expected that SMART is widely cited as the counter-argument to most patients will experience rebound viraemia stopping ART, trials of treatment interruption in soon (within 12 weeks) off ART; however, in the primary infection have not revealed the same degree SPARTAC trial, there was evidence for a correlation of risk.
Load more

Recommended publications
  • Are We Standing in Our Own Way on the Path to a Cure for HIV/AIDS
    PROFILE Are we standing in our own way on the path to a cure for HIV/AIDS lthough there are many reasons to celebrate the life-extending benefits from antiretroviral Atherapeutics (ART) for HIV/AIDS and the ability to chronically manage patients’ disease for decades, the majority of people around the world living with the virus do not have access to ART and those that do, have over decades developed life-threatening side effects. Our inability to identify a cure to HIV lies not only in the as-of- yet failure of the medical research community to identify and develop appropriate means of ridding the body of the virus but also government and industrial policies that promote public opinion exclusively focused on chronic management scenarios instead of broadly exploring innovation for cure. “An inconvenient truth” (Davis Guggenheim) mates of the magnitude of the global forced government policy for early epidemic. As the majority of Ameri - and expanded access to experimental There are approximately 37 million cans are not rountinely tested for HIV, drugs, the medical community and people living with HIV and 39 million the virus can go years without being society are struggling with the fact have died of AIDS-related diseases diagnosed in an HIV positive person. that we are barely managing the HIV since the start of the epidemic in 1981. With these statistics it is no wonder epidemic and AIDS crisis. For years we As of March 2015, only 15 million that every day an estimated 5,600 have been locked into thinking of people have access to treatments for people globally become newly infected solutions in terms of a chronic disease HIV.
    [Show full text]
  • HIV/AIDS and Cancer Cure: Is It the Same Battle?
    HIV/AIDS and Cancer cure: Is it the same battle? Monsef Benkirane Molecular Virology Laboratory [email protected] IAS HIV Cure & Cancer Forum Paris, France www.iasociety.org Dynamic of imatinib-treated Chronic Myeloid Leukemia Mature cancer cells Highly divinding Cancer Stem cells www.iasociety.org Persistence and resistance are theBarriers to Cure HIV/AIDS Cancer Latent provirus Quiescent / slow-cycling Quiescent/ slow-cycling Long-lived Long-lived Indefinite proliferative potential Non sensitive to ART Enhanced repair capacity Not visible to the immune system highly resistant to DNA HIV-specific CD8 T cell response damage/Tolerance decreases with cART Enhanced checkpoint kinase expression drug efflux transporter Renewed by dedifferentiation of proliferating cancer HIV/AIDS and cancer are Residual diseases Although their molecular bases are different, similar cure strategies are being developed www.iasociety.org which cure and how to achieve it? Two main strategies are being pursued Eradication, which will require a complete elimination of infected cells, for which the Berlin patient represents a proof of concept. Considering the Boston patients, eradication will require elimination of HIV infected cells and replacement with HIV resistant cells. Remission: HIV controllers and the VISCONTI patients suggest that remission is achievable. This strategy should include monitoring of inflammatory and procoagulant indices. – Find and diminish size of the reservoir (LRAs, bNAbs, CAR-T cell) – Reduce seeding of latent pool with early/more ART – Reverse latency (LRAs, TLR7) – Increase HIV-specific immune function (vaccines or anti PD-L1) – Reduce immune activation – Gene therapy targeting the virus and the host – Allogeneic stem cell transplantation Combination therapy may be necessary While proof-of-concepts are there, we still have to gain important knowledge to achieve HIV eradication or remission Strategies to eradicate latent reservoirs.
    [Show full text]
  • (Rftca) Accelerates a Global Cure for Aids with License of Chromocell’S Proprietary Cell Engineering Technology
    RESEARCH FOUNDATION TO CURE AIDS (RFTCA) ACCELERATES A GLOBAL CURE FOR AIDS WITH LICENSE OF CHROMOCELL’S PROPRIETARY CELL ENGINEERING TECHNOLOGY • The Chromovertâ Technology platform provides an opportunity to create a scalable cell therapy cure for HIV/AIDS by enabling the purification of sufficient numbers of curative cells following the use of other biotechnologies already demonstrated to engineer cells that mimic natural biological resistance to HIV/AIDS; • With this technology, RFTCA will establish a new and charitable non-for-profit research incubator hub in order to research, develop and commercialize a safe and scalable cure for all those in need, regardless of ability to pay; • Chromovert Technology was invented at The Rockefeller University by Kambiz Shekdar, Ph.D., and is pioneered and owned by Chromocell Corporation, a life sciences company that was spun-out of the university. September 4, 2019 – NEW YORK, NY. – Research Foundation to Cure AIDS (RFTCA) has obtained a worldwide license to biotechnology known as Chromovertâ Technology, to research, develop and commercialize a cure for HIV/AIDS. This is the first and only case of an IRS Code § 501(c)3 not-for-profit organization holding rights to biotechnology with the promise to cure AIDS. RFTCA’s mission is to develop an AIDS cure and to make it available and affordable to all of the 37 million people living with HIV/AIDS worldwide. The emphasis in the medical community, until recently, has been on containing the AIDS epidemic with treatment and prevention alone. But recent advances in stem cell biology and cellular engineering have created new opportunities that could lead to a global cure.
    [Show full text]
  • Editing a Cure
    MILESTONES infection and prompted further research into gene-based therapies to genome editing target HIV. Although genome editing had had been been proven efficient in rendering proven efficient T cells refractory to HIV infection, in rendering it was not until years later, in 2014, T cells that a team led by Pablo Tebas and Carl June at the University of refractory to Pennsylvania in Philadelphia showed HIV infection this could be done in infected Credit: Bloomberg/Rob Waters via Getty Images Getty via Bloomberg/Rob Waters Credit: individuals. The clinical trial enrolled 12 patients who were infused with autologous CD4+ T cells modified at the CCR5 locus by zinc-finger nucleases (ZFNs). The patients who stopped ART after cell transfusion exhibited slow viral rebound and proliferation of the modified T cells, MILESTONE 18 indicating enhanced control of the virus. Moreover, one study participant with no viral rebound Editing a cure during ART interruption was found to harbor a single mutated copy of CCR5 and after transfusion a large Timothy Ray Brown—also known transplantation and interruption of proportion of this patient’s T cells as the ‘Berlin patient’—is the only antiretroviral therapy (ART). were resistant to HIV. person ever to be cured of HIV. His Although at the time of transplant Together, these findings story and the research that followed Brown also carried HIV variants demonstrated that gene-targeting are intimately linked to the discovery, tropic for the CXCR4 chemokine approaches could provide a safer back in 1996, that homozygosity for receptor, Hütter reasoned that their and more practical approach than a CCR5 allele with a 32-base-pair numbers might have been too low to the risky and restrictive HSCT and deletion (delta32/delta32) renders allow reseeding of the new immune opened the door for ZFNs and some individuals resistant to system.
    [Show full text]
  • HIV Update • HIV Natural History Review • Acute HIV Infection October 10, 2018 • 2018 Top 10 List • Miscellaneous Issues Relevant Jack Stapleton, MD for Primary Care
    10/10/18 HIV Update • HIV natural history review • Acute HIV infection October 10, 2018 • 2018 Top 10 List • Miscellaneous Issues relevant Jack Stapleton, MD for Primary Care Natural History of HIV Infection No Infection Primary HIV Infection Neurologic Disease Exposure PGL to HIV • Also called: Early Infection Asymptomatic Symptomatic AIDS – Acute Retroviral Syndrome, HIV-Mono Disease • Occurs in 40% to 70% of new HIV infections Acute Disease • 1 - 12 weeks post-exposure 0 0.2 0.7 2.2 6.1 7.3 8.1 8.2 8.1 7.4 6.7 n/100 developing AIDS diagnoses • Average duration ~ 1-8 weeks 0 1 2 3 4 5 6 7 8 9 10 years post-infection • Neuropathic and Dermatopathic presentation No Infection Exposure • Antibody test often negative during illness to HIV IRIS Infection Tx Monitor for side effects Acute HIV Infection Fever 87.5 % Malaise 72.5 % Myalgia 60 % Rash 57.5 % Headache 55 % Night Sweats 50 % Sore Throat 42 % Lymphadenopathy 37.5 % Arthralgia 27.5 % Nasal Congestion 17.5 % Oral Ulcers 7.5% Thrush 5 % Ann. Int. Med. 134:25-29, 2001 1 10/10/18 Kinetics of Viral Load and Immune Response CD4 -Agcount NegativeHIV Ab Serology Positive 2018 HIV/AIDS Top 10 Serology HIV RNA HIV RNA CD4 count 1-12 wks 8-10 yrs 2-3 yrs Number 1 HIV – CD4 Cell Interaction • CD4 = Binding • CCR5 and CXCR4 Though not so new – this still makes Entry Corecptors • Transmitted virus = the Top 10 CCR5 • Polymorphism: Evidence for HIV cure by CCR5D32/ CCR5D32 • Mainly Caucasian CCR5D32 stem cell transplantation • Homozygosity = HIV resistance! Timothy Brown – the “Berlin Patient” R5
    [Show full text]
  • Investigating Neuronal Injury in a HIV Cure Strategy
    12th International Symposium on Neuropsychiatry and HIV 14th June 2019 Investigating neuronal injury in a HIV cure strategy Jasmini Alagaratnam Clinical Research Fellow Imperial College London Why can’t ART cure HIV? The viral reservoir HIV reservoir sites Major reservoirs HIV infects CD4+ cells Dormant memory T cells in lymph nodes and blood2 Some become Macrophages and resting memory cells; dendritic cells in various tissues (especially in ‘reservoir’ lymph nodes, gut and central nervous system)2 Research into HIV cure has intensified Data on the safety aspects of HIV cure strategies are limited1 1. Dubé K. Trends Microbiol. 2014 Oct;22(10):547-9 Kick and kill Potential CNS risks of ‘kick and kill’ 1. Direct neuronal injury: • Viral rebound releasing viral proteins which are neurotoxic • LRA toxicities 2. Indirect neuronal injury: • CNS IRIS, CD8+ mediated encephalitis • Following HIV vaccines which may modify immune responses • Inflammation & immune activation • Following viral rebound or HIV vaccines 3. Removal of cells with crucial function 4. Reversal of other integrated viruses in a resting phase CSF Neurofilament Light Chain protein (NFL) • NFL maintains structure of axons • Sensitive and dynamic biomarker of active neuroaxonal damage in the CNS • Elevated concentrations are reported in a variety of neurodegenerative conditions including HIV Plasma neurofilament light chain (NFL) • Highly sensitive assay measuring plasma NFL has recently been developed • Strongly correlates with CSF NFL • Removes the barriers of repeated CSF sampling
    [Show full text]
  • World AIDS Day 2015
    World AIDS Day 2015 Year-by-Year Milestones in HIV/AIDS (Adapted from “The POZ Timeline: Milestones in the HIV/AIDS Pandemic” with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS Action Committee) 1981 • In the June 5 Morbidity and Mortality Weekly Report, CDC reports a rare form of pneumonia in five gay men, which are later determined to be the first published cases of AIDS. • The first AIDS service organization, Gay Men’s Health Crisis (GMHC), is founded in New York City. • U.S. Year-End Statistics: A total of 159 cases of the new disease are recorded during 1981. The Fenway Community Health Center reports the first AIDS case in New England. In Massachusetts, there is a sharp increase in the number of new AIDS cases each year from 1981 through 1990. Between 1985 and 1990, an average of 700 AIDS cases are reported each year. 1982 • CDC introduces the term Acquired Immune Deficiency Syndrome, or AIDS, as a replacement for Gay- Related Immune Deficiency (GRID). • The Community-based KS/AIDS Foundation is formed, which later becomes the San Francisco AIDS Foundation. • U.S. Year-End Statistics: 771 cases of AIDS reported to date, with 618 deaths. 1983 • The primary cause of AIDS is confirmed: French researchers isolate a virus, dubbed LAV, that kills CD4 cells in a patient with AIDS. U.S. scientists make a similar discovery in 1984, involving an isolated virus dubbed HTLV-III. • The Advisory Committee of People With AIDS releases The Denver Principles, officially launching the self-empowerment movement among people living with HIV/AIDS.
    [Show full text]
  • HIV Update: an Epidemic Transformed an Evidence-Based Review of New Developments in HIV Treatment and Prevention
    1.5 HOURS CE Continuing Education HIV Update: An Epidemic Transformed An evidence-based review of new developments in HIV treatment and prevention. ABSTRACT: The field of HIV treatment and prevention has evolved rapidly over the past four decades. New therapies that are more potent and streamlined have transformed HIV into a chronic disease, while the use of such preventive strategies as preexposure prophylaxis and postexposure prophylaxis provide effective options for reducing the risk of HIV infection. These medical breakthroughs have enabled more people liv- ing with HIV (PLWH) to reach older adulthood. But they also mean that nurses are seeing more PLWH who have developed long-term complications of living with HIV or of exposure to antiretroviral therapy, as well as concurrent chronic conditions associated with advanced age. Nurses play a critical role in caring for PLWH and those at risk for HIV infection. This article discusses HIV epidemiology, describes the current state of HIV treatment and prevention, and highlights common comorbidities often seen in PLWH who are over age 50. Keywords: HIV, older adults, PEP, postexposure prophylaxis, preexposure prophylaxis, PrEP, prevention, treatment wasn’t supposed to be here,” said John Mar- prevention of HIV over the past several decades, chese to the nurse as he watched the last few patients like Mr. Marchese are no longer a rarity. “I drops of his chemotherapy drug infuse into Nearly 38 years after the Centers for Disease Con- the port implanted in his chest. (This case is a com- trol and Prevention (CDC) reported that five young, posite based on my experience.) The nurse caring for white, previously healthy gay men in Los Angeles had him smiled while preparing to disconnect his iv tub- been diagnosed with pneumocystis pneumonia and ing and flush the port.
    [Show full text]
  • Shank Retroviruses and AIDS 2017
    Retroviruses and AIDS 12/8/17 Peter Shank, Professor Emeritus of Medical Science [email protected] ■ History of retroviruses ■ Biology of HIV/AIDS and some advances in the last decade AIDS death rate males age 25-44 History ■ Vallee and Carre 1904 equine infectious anemia was a “filterable” agent ■ Ellermann and Bang 1908 leukemia in the chicken was a “filterable” agent ■ Peyton Rous 1911 sarcoma in chickens caused by “filterable” agent ■ Bittner 1942 mammalian RNA tumor virus Mouse Mammary Tumor Virus (MMTV) ■ 1970 Baltimore and Temin simultaneously discover Reverse Transcriptase in retroviruses ■ 1976 Bishop and Varmus discover the src gene has a counterpart in normal cells History Cont. ■ 1980 a retrovirus associated with human leukemia HTLV-I ■ 1983 a retrovirus associated with acquired immune deficiency syndrome HTLV-III, ARV or LAV now HIV 1975 Nobel Prize in Medicine ■ David Baltimore ■ Howard Temin 1934- 1994 ■ Prize was shared with Renato Dulbecco Bishop and Varmus ■ Recipients of the 1989 Nobel Prize in Medicine Harold also wrote a memoir in 2009 Varmus in his Nobel lecture said: ■ In describing the formation of RSV DNA ■ “These problems were solved by the unexpectedly elegant configuration of viral DNA, as worked out mainly by Peter Shank, Steve Hughes, and Hsing-Jien Kung in our group.” Nobel Prize in Medicine 2008 Luc Montagnier Francois Barre-Sinousi shared with Harald vur Hausen Retrovirus Structure ■ Positive polarity RNA ca. 7-11 kb ■ RNA capped and polyadenylated but doesn’t function as mRNA ■ Enveloped particles
    [Show full text]
  • First Man Cured of HIV Dies of Cancer: Charity 30 September 2020
    First man cured of HIV dies of cancer: charity 30 September 2020 The first person to be cured of HIV, Timothy Ray foundation. Brown—known as the "Berlin Patient"—has died after a battle with cancer, the International Aids "I am living proof that there could be a cure for Society (IAS) announced Wednesday. AIDS," he told AFP in 2012. "It's very wonderful, being cured of HIV." Brown made medical history and became a symbol of hope for the tens of millions of people living with 'Champion' the virus that causes AIDS when he was cured more than a decade ago. Ten years after Brown was cured, a second HIV sufferer—dubbed "the London Patient"—was He had been living with a recurrence of leukaemia revealed to be in remission 19 months after for several months and received hospice care at undergoing a similar procedure. his home in Palm Springs, California. The patient, Adam Castillejo, is currently HIV-free. "On behalf of all its members... the IAS sends its In August a California woman was reported to have condolences to Timothy's partner, Tim, and his no traces of HIV despite not using anti-retroviral family and friends," said IAS President Adeeba treatment. Kamarulzaman. It is thought she may be the first person to be cured "We owe Timothy and his doctor, Gero Hutter, a of HIV without undergoing the risky bone marrow great deal of gratitude for opening the door for treatment. scientists to explore the concept that a cure for HIV is possible." Sharon Lewin, president-elect of the IAS and director of the Doherty Institute in Melbourne, Brown was diagnosed with HIV while was studying Australia, praised Brown as a "champion and in Berlin in 1995.
    [Show full text]
  • First Man Cured
    Why the London Patient matters: What does a second HIV 'cure' mean? By now, many people have heard the news that there was a second man ‘cured’ of HIV. It was a top headline last week, based on a presentation of research at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) – one of the premier scientific conferences for HIV-related research. Some are saying, “I didn’t know someone had already been cured.” Others ask, “Was he really cured?” Importantly, many people living with HIV are asking, “How does this apply to me?” First Man Cured Scientists in the field agree that the first man deemed cured of his HIV infection is Timothy Ray Brown, who underwent a stem-cell transplant in Berlin in 2007. For years, he was known only as, the ‘Berlin Patient,’ until he went public with his identity in 2010, as he wanted to be part of the search for a cure for HIV. Brown was not trying to cure his HIV infection when he agreed to a stem-cell transplant more than a decade ago. His main concern was life-threatening acute myeloid leukemia that hadn’t responded to chemotherapy. The transplant was a desperate attempt to cure his deadly cancer. He endured two stem-cell transplants, intense conditioning, full body irradiation, a bout with graft-versus-host disease and neurological damage, but eventually From left to right, Julie Patterson, London Patient doctor Dr. Ravi Brown defeated his cancer. Gupta, Timothy Ray Brown, and U=U founder Bruce Richman at CROI 2019 (Photo credit: Bruce Richman) Simultaneously, he had stopped taking his anti-retroviral therapy (ART) and a few months later, he discovered that his HIV was in remission.
    [Show full text]
  • Full Recommendations: Towards an Hiv Cure 2016 Contents
    FULL RECOMMENDATIONS: TOWARDS AN HIV CURE 2016 CONTENTS INTRODUCTION ............................................................................................................................................................................... 4 1. MOLECULAR BIOLOGY OF HIV LATENCY AND REVERSAL STRATEGIES .............................................................7 2. VIRAL RESERVOIRS, IMMUNOLOGY OF HIV PERSISTENCE AND “KILL” STRATEGIES ..................................13 3. MODELS FOR HIV CURE OR SUSTAINABLE REMISSION AND PAEDIATRIC HIV CURE ...............................21 4. GENE AND CELL THERAPY ................................................................................................................................................... 27 5. NOVEL BIOMARKERS AND TECHNOLOGIES TO ANALYSE AND QUANTIFY HIV RESERVOIRS .............33 6. SOCIAL SCIENCES AND HEALTH SYSTEMS RESEARCH ...........................................................................................39 7. METHODOLOGY ........................................................................................................................................................................46 8. ACKNOWLEDGEMENTS ..........................................................................................................................................................46 9. BIBLIOGAPHY .............................................................................................................................................................................. 47 FULL RECOMMENDATIONS
    [Show full text]